1. Home
  2. Analysis
  3. Potassium-gluconate
  4. Ibrance

Potassium gluconate and Ibrance drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Potassium gluconate (potassium) and Ibrance (palbociclib). Common drug interactions include fatigue among females and death among males.

The phase IV clinical study analyzes what interactions people have when they take Potassium gluconate and Ibrance. It is created by eHealthMe based on reports of 57 people who take the same drugs from the FDA, and is updated regularly.

What is Potassium gluconate?

Potassium gluconate has active ingredients of potassium. It is often used in hypokalemia. eHealthMe is studying from 2,901 Potassium gluconate users. Check the latest studies of Potassium gluconate.

What is Ibrance?

Ibrance has active ingredients of palbociclib. eHealthMe is studying from 104,434 Ibrance users. Check the latest studies of Ibrance.

On Jul, 26, 2026

57 people who take Potassium gluconate and Ibrance together, and have interactions are studied.

Potassium gluconate and Ibrance drug interactions.

What are the common drug interactions of Potassium Gluconate and Ibrance, by gender? *:

female:

  1. Fatigue (feeling of tiredness)
  2. Thrombosis (formation of a blood clot inside a blood vessel)
  3. Abdominal discomfort
  4. Constipation
  5. Sinusitis (inflammation of sinus)
  6. Anxiety
  7. Back disorder
  8. Decreased appetite
  9. Depression
  10. Ear discomfort

male:

  1. Death

What are the common drug interactions of Potassium Gluconate and Ibrance, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

  1. Fatigue (feeling of tiredness)
  2. Rash pruritic (redness with itching)
  3. White blood cell count decreased
  4. Urinary tract infection

50-59:

  1. Tooth extraction
  2. Dizziness
  3. Nausea (feeling of having an urge to vomit)
  4. Vomiting
  5. Arthralgia (joint pain)
  6. Back pain
  7. Cardiac disorder
  8. Dyspnoea (difficult or laboured respiration)
  9. Nasopharyngitis (inflammation of the nasopharynx)
  10. Tachycardia (a heart rate that exceeds the range of 100 beats/min)

60+:

  1. White blood cell count decreased
  2. Fatigue (feeling of tiredness)
  3. Anxiety
  4. Back disorder
  5. Depression
  6. Ear discomfort
  7. Fungal infection
  8. Oral candidiasis (fungal infection of mouth)
  9. Constipation
  10. Dizziness

What are the existing conditions these people have? *

  1. Breast Cancer Female: 30 people, 52.63%
  2. Breast Cancer: 11 people, 19.30%
  3. Breast Cancer Metastatic: 5 people, 8.77%
  4. High Blood Pressure: 4 people, 7.02%
  5. Nausea And Vomiting: 3 people, 5.26%
  6. Nausea (feeling of having an urge to vomit): 3 people, 5.26%
  7. Hypersensitivity: 3 people, 5.26%
  8. High Blood Cholesterol: 3 people, 5.26%

* Approximation only. Some reports may have incomplete information.

Do you take Potassium gluconate and Ibrance?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Potassium gluconate and Ibrance:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Potassium gluconate:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Ibrance:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Potassium gluconate and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Ibrance and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on potassium and palbociclib (the active ingredients of Potassium gluconate and Ibrance, respectively), and Potassium gluconate and Ibrance (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.